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Abstract
DNA-processing enzymes, such as the topoisomerases (tops), represent major targets for potent anticancer (and antibacterial) agents. The
drugs kill cells by poisoning the enzymes’ catalytic cycle. Understanding the molecular details of top poisoning is a fundamental requisite for
the rational development of novel, more effective antineoplastic drugs. In this connection, sequence-specific recognition of the top–DNA
complex is a key step to preferentially direct the action of the drugs onto selected genomic sequences. In fact, the (reversible) interference of
drugs with the top–DNA complex exhibits well-defined preferences for DNA bases in the proximity of the cleavage site, each drug showing
peculiarities connected to its structural features. A second level of selectivity can be observed when chemically reactive groups are present in
the structure of the top-directed drug. In this case, the enzyme recognizes or generates a unique site for covalent drug–DNA binding. This
will further subtly modulate the drug’s efficiency in stimulating DNA damage at selected sites. Finally, drugs can discriminate not only
among different types of tops, but also among different isoenzymes, providing an additional level of specific selection. Once the molecular
basis for DNA sequence-dependent recognition has been established, the above-mentioned modes to generate selectivity in drug poisoning
can be rationally exploited, alone or in combination, to develop tailor-made drugs targeted at defined loci in cancer cells. D 2002 Elsevier
Science B.V. All rights reserved.
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1. Introduction
DNA topoisomerases (tops) are essential enzymes
present in all organisms [1,2]. They modify DNA topology
in connection with a number of nuclear processes, such as
replication, transcription, chromatin remodeling, chromatin
condensation/decondensation, recombination and repair [3].
All tops can introduce breaks into DNA segments: type II
tops transport a double helical portion of DNA through a cut
involving both strands of another double-helical region;
type I enzymes produce single-stranded breaks, and then
either transport a DNA segment through the break (type I-
A) or allow rotation of the broken strand around the intact
strand (type I-B) [4,5]. In the human genome, five DNA
tops are presently known: two type II tops (top2a and
top2h), a type I-B enzyme (top1) and two type I-A enzymes
(top3a and top3h) [1].
Top1 and top2 have been shown to represent the princi-
pal targets of effective antitumor drugs and, hence, have
deserved investigation to understand the biochemical and
pharmacological basis of drug action [6]. Indeed, topoiso-
merase poisons, such as antitumor drugs, transform these
essential enzymes into lethal DNA-damaging agents. Cir-
cumstantial evidence indicates that top2 (and top1) can
initiate cellular processes that eventually lead to chromoso-
mal translocations and cell transformation [7,8]. Thus, a full
understanding of molecular mechanisms of DNA topoiso-
merase functions leading to cell death and/or genome
alterations may reveal unique opportunities to successfully
treat human cancers.
2. The catalytic process and its poisoning
The enzymatic cycle of top1 [2], largely shared by top2
[9], can be divided into four steps: (1) binding of the enzyme
to DNA, (2) DNA cleavage, (3) strand passage and (4) DNA
0925-4439/02/$ - see front matter D 2002 Elsevier Science B.V. All rights reserved.
PII: S0925 -4439 (02 )00077 -7
Abbreviations: top, topoisomerase; DNA, deoxyribonucleic acid; ATP,
adenosine triphosphate; CPT, camptothecin; AmC, cytosine arabinoside;
m-AMSA, amsacrine; ET, ecteinascidin 743; CL, clerocidin; XK469, 2-{4-
[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid; VM-26, tenipo-
side; dh-EPI, 4-demethoxy-3V-deamino-3V-hydroxy-4V-epi-doxorubicin; da-
IDA, 4-demethoxy-3V-deamino-4-deoxy-4V-epiaminodaunorubicin
* Corresponding author. Tel./fax: +39-49-8275-711.
E-mail address: manlio.palumbo@unipd.it (M. Palumbo).
www.bba-direct.com
Biochimica et Biophysica Acta 1587 (2002) 145–154
religation. Once the protein and the nucleic acid are bound
to each other, the phenolic OH of a tyrosine residue in the
catalytic pocket reacts with a DNA phosphodiester bond by
a transesterification process, producing a covalent enzyme–
DNA intermediate linked through a phosphotyrosine bond
(cleavage complex), while the DNA strand is cleaved.
Cleavage may occur simultaneously on both strands in
the presence of top2 enzymes, whereas it involves only
one strand in the presence of top1 enzymes. In type I-A and
type II topoisomerases, the enzyme becomes linked to the
5V-end of the cleaved phosphodiester bond, whereas in type
I-B enzymes, it is bound to the 3V-end. The third step
consists in the strand passing process, which involves a
conformational rearrangement of the enzyme to allow one
or both strands of DNA to pass through the gap generated
by the cleavage step. The final religation process corre-
sponds to the attack of the free 5V- or 3V-hydroxyl terminus
of the cleaved bond onto the phosphotyrosine linkage to
reseal the original phosphodiester bond. Then, enzyme
release occurs (Fig. 1). Given the energy requirements of
the enzyme, ATP binding and hydrolysis has to be included
in the catalytic cycle of top2.
In the presence of a drug which is able to affect the DNA
cleavage-religation process by increasing the DNA cleavage
rate or by reducing the DNA religation rate, the cleavage
complex has a longer life and DNA breaks persist [10,11].
This action converts top2 into an endogenous toxin that
stabilizes damage in the genome and triggers a series of
apoptotic events that finally lead to cell death. There are
several modes for a drug to affect the cleavage complex, but
it is generally believed that a ternary complex is formed, in
which the drug is bound to the DNA and the enzyme
simultaneously [2,9]. Hence, there will be normally two
pharmacophoric regions in a poison molecule, one facing
(and interacting with) the enzyme and the other the nucleic
acid.
3. Structures of topoisomerase poisons
A large number of compounds have been shown to
interfere with top (principally top2) activity, and they
exhibit a variety of structural features [2,9,12,13]. The
structures of selected compounds are shown in Fig. 2.
Fig. 1. Schematic representation of the chemical processes occurring in the topoisomerase catalytic cycle. The tyrosine residue at the active site (left) can attack
a phosphodiester bond of DNA, giving a phosphotyrosine adduct linked either at the 3V(upper reaction scheme) or at the 5V(lower reaction scheme) position.
This will produce a cut in the DNA chain leaving a free 5Vor 3Vhydroxyl group.
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Clinically useful top1 poisons include the natural com-
pound camptothecin (CPT) and its synthetic analogues
topotecan and irinotecan. In addition, minor groove binders,
such as the bisbenzimidazoles Hoechst 33258 and Hoechst
33342, and the indolocarbazoles derived from rebeccamy-
cin, were found to be top1 inhibitors.
Fig. 2. Selected chemical structures of topoisomerases I and II poisons.
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Top2 poisons include drugs from different families, such
as epipodophyllotoxins, anthracyclines, acridines, anthra-
quinones, ellipticines, bisantrene, actinomycin D, terpe-
noids, quinolones and flavonoids. It is difficult to envisage
common structural features among them. In fact, some of
the compounds do not bind to DNA, while others exhibit a
high affinity for the nucleic acid. In particular, very effective
are the intercalators (anthracyclines, anthracenediones, acri-
dines, bisantrene, actinomycin). They are characterized by a
planar polycyclic DNA-intercalating region, to which polar
side chain groups are eventually attached. The planar region
is supposed to be able to slip between DNA bases and
generate efficient stacking interactions with them. This is
likely to represent the DNA-binding domain in the cleavage
complex. In addition, to further stabilize contacts with the
nucleic acid, the side-chains are likely to interact with the
enzyme, thus, acting as enzyme-recognition elements.
Indeed, in addition to their chemical structure, the relative
position of the (planar ring/side chain) pharmacophores
plays a major role in modulating nucleic acid binding and
enzyme poisoning effects [14–16]. Non-DNA-binders, like
epipodophillotoxins, can also stabilize the cleavage com-
plex. In this case, perhaps, stronger contacts are formed with
the enzyme to compensate for poor interaction with the
nucleic acid. Indeed, recent studies show that both the
recombinant N-terminal ATPase domain and the BVAVcore
domain of human top2a bind etoposide specifically, even in
the absence of DNA. [17].
Dual top1 and top2 inhibitors have finally been
described. Among others, they include saintopin, intopli-
cine, aclarubicin [18], acridine-4-carboxamide derivatives
[19], bis(phenazine-1-carboxamides) [20], indeno-quino-
lines, [21] acetyl-boswellic acids [22] and fluorinated lip-
ophylic epipodophylloids [23]. As with top2 poisons,
different structural types are found, including intercalating
and nonintercalating agents.
4. DNA sequence specificity of topoisomerase poisoning
4.1. Classical drugs
It has become evident that poisoning of the top–DNA
cleavage complex by anticancer drugs does not occur at
random along the DNA chain, but follows well defined
rules, as demonstrated by the sequence analysis of the DNA
regions where cutting had been stimulated by the top poison
[24–26]. Top activity on the genome exhibits per se a
certain degree of specificity. Indeed, significant nucleotide
preferences were found in the regions flanking the cleavage
site, often corresponding to alternating purine–pyrimidine
tracts [27,28]. However, site selectivity exhibited by the
poisons is more efficient and dependent on the poison’s
nature. Compounds of different chemical classes stimulate
specific cleavage patterns in DNA fragments, which do not
comprise all of the sites recognized by the enzyme. More-
over, the effects of specificity are principally due to the base
immediately preceding ( 1) or following ( + 1) the cleav-
age site [29]. These findings confirm that the drugs are
localized at (or very close to) the enzyme active site, and
possibly contact both components of the cleavage complex.
Localization of amsacrine at the active site has been
demonstrated, using a covalently binding azido derivative,
which was found to localize the drug molecule at the  1
and + 1 positions in the presence of top2 [30]. Another
similar example is a reactive CPT derivative bound to top1
[31].
A peculiar case seems to be that of nogalomycin [32],
which has been proposed to bind to an upstream site (from
position  6 to  3) to provide a DNA structural bend that
stimulates highly specific top1-mediated DNA cleavage. In
this case, the drug would act at a distance from the catalytic
site, like an allosteric effector.
An interesting mechanism is exhibited by the antimeta-
bolite cytosine arabinoside (AraC) [33]. Lesions generated
when the drug is incorporated into chromosomal DNA
behave as position-specific top2 poisons and stimulate
DNA cleavage mediated by the human type II enzymes.
Moreover, additive or synergistic increases in DNA cleav-
age were observed in the presence of AraC lesions and
etoposide, pointing to the possibility that the sequence-
specific lesions might result from a combination of pro-
cesses.
A question which arises when considering drug sequence
specificity in producing protein-mediated DNA damage is
related to possible species-related effects. This issue was
recently addressed by Strumberg et al. [34], who performed
a molecular analysis of drug interactions in yeast and human
type II tops. Similarities and differences in DNA cleavage
patterns and nucleic acid sequence preferences were
observed between the human, yeast and E. coli top2
enzymes in the presence of the nonintercalators fluoroqui-
nolone (CP-115,953), etoposide and azatoxin and the inter-
calators amsacrine and mitoxantrone. Additional base
preferences were generally observed for the yeast, when
compared with the human top2a, enzyme. Preferences in
the immediate flanks of the top2-mediated DNA cleavage
sites were, however, consistent with the drug-stacking
model for both enzymes. Homologous mutations in yeast
and human top2 decreased the reversibility of the drug-
stabilized cleavage sites and produced consistent base
sequence preference changes. These data indicate that the
structure of the enzyme/DNA interface plays a key role in
determining the specificity of top2 poisons and cleavage
sites for both the intercalating and nonintercalating drugs.
These effects must be borne in mind when comparing
results obtained with topoisomerase enzymes of different
origin. The principal base preferences exhibited by the
drugs, thus, far investigated are summarized in Table 1.
Confirming the above-mentioned location of the drug at
the enzyme active site, the principal preferences for DNA
cutting correspond to the bases located at positions  1/ + 1.
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Generally, drugs having a strong  1 preference do not
exhibit a strong + 1 preference. This represents an indica-
tion that effective recognition of DNA by a drug is carried
out either on one side or on the other of the cleavage
complex, the drug molecule being principally located either
upstream or downstream the cleaved phosphodiester bond.
A closer examination of individual specificities shows
that a purine residue is invariantly found to be preferred at
+ 1, both by top1 and top2 poisons. Considering the large
planar portions of these drugs, this could indicate that
DNA–drug stacking effects are operating in the ternary
complex with the enzyme. Instead, the majority of  1
specific agents accept both pyrimidines and purines in the
cut strand. Although the list of  1 specific agents includes
nonintercalating agents, the majority of the compounds in
this list are also intercalators, which prefer stacking inter-
actions, so that the presence of pyrimidine preferences are
not easily explainable at first glance. However, if we
consider that all  1 specific agents are top2 poisons, and
that the  1 base remains essentially paired to the comple-
mentary base located in the intact strand, the poison at  1
would always have a complete base pair to make contacts
with, irrespective of the presence of a purine or a pyrimidine
at the scissile strand.
It is very difficult to rationalize coupling of drug struc-
tures with corresponding specificities. The task could be
made much easier, having tridimensional structures of the
cleavage complex or, even better, of the ternary complex
containing the drug.
Combining the biochemical and structural evidence, two
models of the receptor site of CPT on the covalent complex
of human top1 and DNA have been proposed [35,36]. Both
attempt to explain the results of numerous CPT structure
activity studies, and of investigations on drug-resistant top1
mutants. One model [35], schematically shown in Fig. 3A,
uses the crystal structure of the human top1–DNA covalent
complex and places the CPT molecule into the DNA duplex
in a position that partially overlaps with the + 1 guanine of
the scissile strand; this placement requires the guanine base
to flip out of the duplex and stack on the planar CPT. A
second model [36] foresees intercalation of CPT into a B-
form DNA duplex and models the positions of the phos-
photyrosine723 and Asn722 residues as well (Fig. 3B). CPT
occupies very different positions in the two models, neither
of which can fully explain the experimental findings. In
particular, no indication emerges for the requirement for a
guanine at the + 1 position of the scissile strand, as
established by early investigations [25,26]. A theoretical
structural model has been obtained very recently [37] by
docking CPT into the top1–DNA cleavage complex
obtained from X-ray data. The model of the lowest energy
complex (Fig. 3C) is consistent with intercalation of the
drug at the cleavage site, with the A-ring directed toward the
major groove and the E-ring pointing into the minor groove.
As shown in Fig. 3, the drug’s orientation differs remarkably
in the previous intercalation model [36], while it is similar in
the guanine-flipping model [35]. Perhaps, publication of the
X-ray structure of the ternary cleavage complex with top-
otecan, announced by Stewart et al. [38] at the 2001 AACR
meeting will settle the question.
Table 1
Base preferences of selected topoisomerase poisons
 1a + 1a
Poison Base
preference
Poison Base
preference
Doxorubicinb A Amsacrineb A
Etoposideb C(T) Bisantreneb A
Mitoxantroneb C/T Camptothecinc G
Ellipticineb T Indolocarbazolec G
Amonafideb C Saintopind G
Genisteinb T
a Position from the cleavage site.
b top2 poisons.
c top1 poisons.
d Dual poison.
Fig. 3. Proposed orientations of CPT bound to DNA in the ternary CPT–
DNA–top1 cleavage complex. DNA bases are viewed from the helix axis
and schematically drawn as rectangles. Solid lines correspond to the pair at
the  1 position (see text), while dashed lines correspond to the pair at + 1.
CPT is located between the  1 and + 1 bases. (A) Flipping guanine model
from Ref. [35]. (B) Intercalation model from Ref. [36]. (C) Intercalation
model from Ref. [37].
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An example of modulation of cleavage specificity is
represented by homocamptothecin, containing a seven-mem-
bered h-hydroxylactone ring in place of the conventional six-
membered a-hydroxylactone ring found in CPT [39].
Besides stimulating cleavage by top1 at preferred T.G sites,
the homo derivative stabilizes cleavage at specific AAC.G
sequences as well. Hence, notwithstanding the conserved
primary G+ 1 requirement, the ring homologation procedure
generates a ternary complex structure which can discriminate
up to three bases upstream the cleavage site. Clearly, further
studies are required to fully elucidate the molecular inter-
actions leading to specific DNA damage stimulation by the
CPT family.
The presence of common pharmacophores for similar
specificities of cleavage stimulation, and the importance of
the relative positions of the planar ring system and of the
side-chain groups, has been recently addressed by preparing
amsacrine (m-AMSA)/bisantrene hybrids and bisantrene
isomers [14]. The new compounds were able to poison
DNA top2 with an activity intermediate between those of
bisantrene and m-AMSA. Moving the side-chain from the
central to a lateral ring (from C-9 to C-1/C-4) only slightly
modified the drug DNA affinity, whereas it dramatically
affected local base preferences of poison-stimulated DNA
cleavage. In contrast, switching the planar aromatic systems
of bisantrene and m-AMSA did not substantially alter the
sequence specificity of drug action. A computer-assisted
steric and electrostatic alignment analysis of the test com-
pounds suggested that bisantrene, m-AMSA and 9-substi-
tuted analogs share a common pharmacophore, whereas the
1-substituted isomer showed a radically changed pharmaco-
phoric structure.
A further question arising from this investigation,
approached using the same set of compounds, is a possible
relationship between sequence specificity for DNA in the
presence and in the absence of the enzyme. We should
remember that most of the known top2 poisons are also
good DNA binders. The bisantrene analogues exhibited
different DNA sequence preferences, depending on the
locations of the side-chain groups, which suggests a major
role for the side-chain position in generating specific
contacts with the nucleic acid, even in the absence of
enzyme [40]. More interestingly, the observed preferences
compare well with the alteration of base specificity found
for the top2-mediated DNA cleavage stimulated by the
isomeric drugs. This confirms that not only DNA affinity,
but also DNA-binding specificity, represents per se an
important determinant for the recognition of the topoiso-
merase–DNA cleavable complex by the drug, at least for
poisons belonging to the amsacrine–bisantrene family.
Thus, it has been concluded that the relative space
occupancy and electron distribution of putative DNA bind-
ing (aromatic rings) and enzyme binding (side-chains)
moieties are fundamental in directing the specific action
of top2 poisons and in determining the poison pharmaco-
phore.
4.2. Drug conjugates containing DNA-recognition elements
A useful approach to confer a desired sequence specificity
is to synthesize drug conjugates with structural elements
known to recognize well-defined features of DNA. Since the
target for topoisomerase is a double-stranded helix, the
following targeting elements can be used in combination
with normal drugs: groove-binding AT specific structures,
such as the antibiotics netropsin and distamycin [41–43],
hairpin pyrrole–imidazole polyamides [44] and triplex-form-
ing oligonucleotides [45,46]. In the first two, the conjugates
are tethered to the minor groove; in the third, major groove
binding occurs. The success of the above approaches rests on
the ability to target the nucleic acid without impairing bind-
ing of the topoisomerase. The AT-binder conjugates with
CPT proved to be poorly effective, due to their limited
sequence-recognition properties [43].
Other top1 poisons were covalently attached to triple
helix-forming oligonucleotides. Besides increasing the drug
affinity for DNA, the conjugates were shown to stimulate
top1-mediated DNA cleavage in a triplex-directed sequence-
specific manner [46]. In addition, the results obtained with
drug–polyamide conjugates showed that they were able to
recruit top1 to produce DNA cleavage in high yield [44].
Hence, the new compounds could be considered as new
artificial nucleases. It will be now interesting to verify
whether conjugates targeted to the coding regions of selected
genes will be able to regulate transcription elongation
through a top1-dependent mechanism.
5. Drugs producing covalent adducts in the cleavage
complex
Poisoning of the cleavage complex by the presently used
drugs is a reversible process, and normal processing of the
DNA by the enzyme is restored once the drug is removed
[47]. Since triggering of the cell death events is initiated by
the presence of the cleavage complex, the extent of this
process will depend upon the drug’s in and off kinetics. The
longer the drug is bound to the cleavage intermediate, the
more effective will be induction of apoptosis. Hence, if the
drug becomes permanently linked to the DNA–enzyme
complex, apoptosis signaling should be most prominent.
Compounds bearing DNA-reactive groups, such as the
alkylators [48], usually produce generalized damage to the
nucleic acid and to other cellular structures. Although the
toxicity generated by these compounds is being used for
the treatment of cancer, nonetheless the related side effects
are quite marked. In addition, sequence selectivity is in
general poor, as a large number of reactive group(s) in the
DNA chain are available for targeting at the same time. It
would be much more specific if the drug were to react with
the nucleic acid only when topoisomerase is present. An
enhancement in top activity at specific DNA alkylation
sites has been found using N-methyl-NV-nitro-N-nitroso-
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guanidine [49]. This suggested a role for top1 poisoning by
alkylated bases in the antiproliferative activity of alkylating
agents, as well as in the DNA lesions resulting from
endogenous and carcinogenic DNA modifications.
Other interesting examples are represented by the drugs
psorospermin, ecteinascidin and some analogues [50–53].
These are weak DNA alkylators in the absence of top2 in the
first case and top1 in the second. Significantly, the alkylation
reactivity of psorospermin at specific sites on DNA increased
25-fold in the presence of top2 [50]. In addition, psorosper-
min trapped the top2-cleaved complex at the same sites.
These results imply that the efficacy of psorospermin is
related to its interaction with the top2–DNA complex. The
site of alkylation of psorospermin is within the top2 gate site,
as for other derivatized intercalators used to pinpoint the site
of drug action in the cleavage complex.
Ecteinascidin 743 (ET), a potent antitumor agent from the
Caribbean tunicate Ecteinascidia turbinata, can alkylate
selectively guanine N2 in the DNA minor groove, a process
reversed by DNA denaturation. However, it differs remark-
ably from other DNA alkylating agents presently in the clinic
by both its biochemical activities and its profile of antitumor
activity in preclinical models [52]. A 100-kDa protein was
found to bind to DNA alkylated by ET and was identified as
top1 [52]. DNA alkylation was essential for the formation of
top1-mediated cleavage complexes by ET, and the distribu-
tion of the drug-induced top1 sites was different for ET and
camptothecin, although they still share a G + 1 preference.
These data indicate that DNAminor groove alkylation by ET
is required to produce top1-mediated protein-linked DNA
breaks. Other studies, however, question the relevance of
top1 poisoning by ET (and its synthetic analogue phthalasci-
din) as they show that in vivo top1 cross-linking is poor and
that ET can be cytotoxic independently of top1 expression
[53,54].
A more striking example is represented by clerocidin
(CL) [55–58], reported to produce top2-mediated irrever-
sible cleavage compatible with G-1 preference [57], a
process unusual for topoisomerase poisoning. Since CL
contains chemically reactive epoxy and carbonyl groups,
studies were made to detect possible reaction with DNA.
Indeed, the drug was able to nick negative supercoiled
plasmids per se [58]. Covalent adducts with guanines at
N7 position were formed in topoisomerase-free media,
which were able to trigger phosphodiester bond cleavage
at the modified site. Only single-stranded or distorted
double-helical regions of DNA underwent CL alkylation.
The guanine-alkylating ability of CL suggests an unprece-
dented mechanism of top2 sequence-specific poisoning,
according to which the enzyme renders the drug reactive
toward DNA by changing the local structure of the nucleic
acid and by bringing drug and DNA reactive moieties in
close proximity.
In conclusion, the combination of reversible (the drug
must recognize the cleavage complex) and irreversible (drug
covalent binding occurs only when the drug is appropriately
located at the cleavage site in close contact with the target
reactive group in DNA) effects will contribute to subtly
modulate the drug’s efficiency in stimulating DNA damage
at selected sites.
6. Topoisomerase II isoform specificity
It has recently become evident that top2 is not a single
enzyme in eukaryotic cells, but is present as two isoforms: a
170-kDa one, referred to as a, and a 180-kDa one, referred to
as h. They differ in subcellular localisation and biochemical
properties [59], suggesting that each isozyme has a distinct
cellular function. Hence, studies aimed at evaluating the
differential susceptibility to inhibition by anticancer drugs
and site selectivity are of great help to better understand the
role and actions of the various drugs. In addition, the relative
level of expression of the a and h isoforms may contribute to
the degree of tumor responsiveness to different chemother-
apeutic agents.
The relationship between expression of top2 isoforms and
established prognostic factors and pathological variables was
examined in over 50 primary breast tumor samples [60]. The
expression of the two top2 genes was apparently not coor-
dinately regulated in these tissue samples. Immunohisto-
chemical analysis revealed that top2h was widely
distributed ( > 90% positive tumor cells), but that top2a
expression was less widely expressed. This suggested that
top2a, but not tp2h, expression is dependent upon cellular
proliferation status, but that the more widely expressed top2h
protein may play a significant role as a target for antitumor
therapy. An immunofluorescence technique was also devised
to visualize and quantify isoform-specific cleavable com-
plexes in situ [61].
A number of studies have been performed on the major
classes of anticancer drugs, including acridines, anthracy-
clines, anthraquinones, epipodophyllotoxins, 9-OH-ellipti-
cine [62–70]. The methodological approaches include the
use of human cancer cell lines having defined profiles of
expression of the two enzymes (breast cancer, acute lympho-
blastic leukemias, sensitive and resistant leukemia HL-60),
viz. noncycling cells, where the a isoform is down-regulated,
transgenic cells lacking one isoform, or resistant cells trans-
fected with a plasmid carrying one of the two isoforms. In
addition, biochemical studies were carried out with the
human recombinant enzymes overexpressed and purified
from yeast. All drugs were able to affect both the a and the
h isoform, although to different extents, indicating that both
enzymes are good targets. Hence, the observed differences
are quantitative, not qualitative, and the drugs presently in use
exhibit a low level of discrimination. However, it appears that
the anthracyclines prefer the a enzyme, and amsacrine and
mitoxantrone the h enzyme.
While no very selective top2a poison has been found as
yet, an almost pure top2h poison has been recently identified
[71]. Indeed, the synthetic quinoxaline phenoxypropionic
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acid derivative XK469 possesses unusual solid tumor selec-
tivity and activity against multidrug-resistant cancer cells. In
band depletion assays, XK469 caused little or no depletion of
top2a and a significant dose-dependent reduction of top2h.
In addition, exposure of subconfluent MCF-7 human breast
cancer cells to the drug resulted in substantial cross-linking of
top2h, but not top2a. Inhibition of superhelical DNA relax-
ation was also very effective in the presence of top2h. These
findings indicate that the primary target of XK469 is top2h.
Preferential targeting of this enzyme may explain the solid
tumor selectivity of XK469 and its analogs because solid
tumors, unlike leukemias, often have large populations of
cells in the G(1)/G(0) phases of the cell cycle in which top2h
is highly expressed whereas top2a is not.
It will be very important to define the molecular determi-
nants for preferential top2htargeting by XK469, in order to
define structure–activity relationships for quinoxaline phe-
noxypropionic acid derivatives, and to design new classes of
anticancer agents, perhaps endowed with prominent solid
tumor cell killing potency.
The sequence selectivity of isoenzyme-mediated DNA
cleavage for amsacrine, teniposide (VM-26) and an anthra-
cycline derivative were determined using the human
recombinant enzymes [72,73]. Local base preferences for
DNA cleavage exhibited by the above drugs were essentially
the same for both isozymes and corresponded to those
determined using the murine enzyme. The identical drug
sequence specificities suggest that molecular interactions of
the tested drugs in the ternary complex are likely similar in
the two isozymes. Evidently, the contacts formed between the
tested drugs and the enzyme concern residues conserved in
both isoforms. The high degree of sequence homology found
at the top2 active site [74] justifies the above results. Drugs
which stimulate a and h cleavage at different sites could
possibly be designed by exploiting differential interactions
with the nonconserved residue(s) of the protein’s active site.
To do so, the structure of the cleavage complex must be
appropriately modeled.
7. In vivo specificity of topoisomerase poisoning
A final issue that deserves to be addressed deals with in
vivo sequence-specific stimulation of top-mediated DNA
cleavage and its relationship to in vitro findings. In vitro
experiments are performed with the purified enzyme and a
double helical DNA fragment. The situation in vivo is much
more complicated, as a crowding of different enzymes and
proteins occurs in chromatin, so that topoisomerase has to
find its way by competing with other biological macro-
molecules. In addition, the structure and topology of DNA
in vivo is greatly affected by specific interactions with
histones and DNA-processing enzymes, which could greatly
affect cleavable complex formation and drug interference
both quantitatively and qualitatively. Hence, studies aimed at
defining the exact location of drug-stimulated damage in
living cells are very useful for a proper assessment of the
biological significance of cell-free topoisomerase poisoning
experiments. In addition, specific (different) cleavage loca-
tions generated by each drug along the eukaryotic genome
might substantially contribute to differentiate the anticancer
potential of the drug.
Recent in vivo studies are described by Borgnetto et al.
[75] who investigated DNA cleavage sites stimulated by
three poisons with diverse sequence specificity, CL, VM-26
and the anthracycline dh-EPI in two genomic regions of
Drosophila melanogaster Kc cells. CL-stimulated DNA
cleavage sites were rarer than those of VM-26 at the satellite
locus. In the histone H2A–H2B intergenic region, CL and
dh-EPI stimulated cleavage, whereas VM-26 was only
weakly effective. As observed in vitro, some CL cleavage
sites did not undergo spontaneous reversion, indicating that
this agent can stimulate irreversible cleavage in vivo. Direct
genomic sequencing showed that many CL and dh-EPI sites,
although distinct, mapped to the transcription start and to the
proximal promoter of the H2A gene. Hence, the in vivo
specificity of topoisomerase poisoning is likely to arise from
a combination of chromatin accessibility and local drug-
related preferences.
DNA cleavage sites stimulated by the two anthracyclines
dh-EPI and da-IDA were investigated at the histone gene
cluster of cultured Drosophila Kc cells [76]. The two agents
produced closely related patterns of double-stranded DNA
cleavage in Kc cell chromatin. Analyses of numerous base
sequences of dh-EPI and (fewer) of da-IDA sites showed that
both compounds largely followed the in vitro requirement of
(5)VTA at 3V ends of cleaved strands. Nonetheless, a mod-
ulation in DNA cleavage was found when using human top2
isoforms in vitro. Human top2a promoted cleavage patterns
that were much more similar to those of Drosophila top2 than
human top2h. Moreover, da-IDA showed a marked site-
dependent preference for human top2 h, suggesting that,
notwithstanding the similarities found comparing the in vivo
and in vitro data, differential effects on the two isozymes
might influence drug activity in human cells.
8. Conclusions
Specificity is a fundamental feature of effective drugs, to
prevent simultaneous recognition of multiple targets and,
hence, the onset of undesired side effects. Although the
treatment of cancer often requires the use of potent cytotoxic
compounds, poorly selective between normal and cancer
cells, important knowledge is being acquired on the mecha-
nisms of recognition of biological targets by effective drugs.
In this context, topoisomerases are useful targets to be
exploited for specificity. Available results indicate that the
biologically relevant specific DNA-binding properties of
topoisomerase poisons occur through a protein-mediated
process. Hence, the cleavage complex interface represents a
unique structural feature, differing from DNA-sequence to
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DNA-sequence. Small molecules are able to fit into this
intermediate and generate site-selective contacts with the
enzyme–DNA adduct. By properly exploiting the drug’s
ability to recognize more specifically its target, it should be
possible to rationally design compounds able to transform the
topoisomerase into an endonuclease that cleaves DNA at
very few selected sites along the genome, thus, triggering the
apoptotic process in malignant cells only. This will hopefully
yield new powerful anticancer agents, able to distinguish
between mutated and normal DNA, hence, to spare healthy
cells from death. Although we are still far from being able to
do so, the combined information on reversible, irreversible,
type and isoform specificities exhibited by the topoisomerase
poisons is rapidly yielding the seminal knowledge to suc-
cessfully proceed in that direction.
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